| Predicate |
Object |
| contentType |
Comment|Journal Article |
| endingPage |
627 |
| issn |
1759-5037
1759-5029 |
| issueIdentifier |
11 |
| pageRange |
627-627 |
| publicationName |
Nature reviews. Endocrinology |
| startingPage |
627 |
| bibliographicCitation |
Ozerlat I. Thyroid gland: vandetanib for thyroid cancer. Nat Rev Endocrinol. 2012 Nov;8(11):627. doi: 10.1038/nrendo.2012.157. PMID: 22926096. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_77f0899016395916bcdbe4936cfc4f7b |
| date |
2012-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| identifier |
https://doi.org/10.1038/nrendo.2012.157
https://pubmed.ncbi.nlm.nih.gov/22926096 |
| isPartOf |
https://portal.issn.org/resource/ISSN/1759-5037
https://portal.issn.org/resource/ISSN/1759-5029
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/35765 |
| language |
English |
| source |
https://www.crossref.org/
https://scigraph.springernature.com/
https://pubmed.ncbi.nlm.nih.gov/ |
| title |
Thyroid gland: vandetanib for thyroid cancer |
| discussesAsDerivedByTextMining |
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9419
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3081361 |